Skyrizi 75 mg, lnjektionslösung in einer Fertigspritze

7680669440015 CH-66944 Fertigspritze
Skyrizi 75 mg, lnjektionslösung in einer Fertigspritze
Skyrizi 75 mg, lnjektionslösung in einer Fertigspritze
Skyrizi 75 mg, lnjektionslösung in einer Fertigspritze
1 / 3
google

Article details

Package size
2
Selling units
2
Measure
Fertigspritze(n)
Galenic form
Fertigspritze
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
08/02/2026
Summary of Product Characteristics
Français
08/02/2026
Summary of Product Characteristics
Italien
08/02/2026

Detailed composition

Substance Quantity Type Category
alcohol isopropylicus
- Substance HNIDK
risankizumabum
75.0 MG Substance Wirkstoff (Principe actif)
sorbitolum
34.0 MG Substance HBESI
dinatrii succinas hexahydricus
- Substance HNIDK
natrium
0.149 MG Substance HBESI
natrium
0.149 MG Substance HBESI
acidum succinicum
- Substance HNIDK
polysorbatum 20
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK

Authorization holder

AbbVie AG

6330 Cham

Authorization information

Swissmedic authorization number
66944
Drug name
Skyrizi, lnjektionslösung in einer Fertigspritze
Galenic form
INLFS
ATC Code
L04AC18
Authorization status
Z
Dispensing category
B
First authorization
18/04/2019
Authorization expiration date
31/12/9999
IT Number
07.15.0.
Domain
Human medicine
Field of application
Plaque-Psoriasis bei Erwachsenen, Psoriasis-Arthritis

Package details

Description (FR)
SKYRIZI Sol inj 75 mg/0.83ml Ser prér, 2pce
Description (DE)
SKYRIZI Inj Lös 75 mg/0.83ml Fertspr, 2Stk
Market launch
18/04/2019
Narcotic (BTM)
No

Other package sizes (1)

SKYRIZI Sol inj 150 mg/ml Ser prér, 1pce
1 FESP
GTIN: 7680669440022
View
Buy us a coffee Explore the data